Aprea Therapeutics, Inc. (NASDAQ: APRE)

Sector: Healthcare Industry: Biotechnology CIK: 0001781983
Market Cap 3.67 Mn
P/B 0.34
P/E -0.28
P/S 7.52
ROIC (Qtr) -113.59
Div Yield % 0.00
Rev 1y % (Qtr) -99.48
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Aprea Therapeutics, Inc. (NASDAQ: APRE), a clinical-stage biopharmaceutical company, is dedicated to the development of novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. The company's operations are primarily focused on researching and developing small molecule inhibitors that selectively kill cancer cells while sparing normal cells. Aprea Therapeutics operates in the biopharmaceutical industry and has a presence in various countries, with its main operations being conducted in the United States. The...

Read more

Investment thesis

Bull case

  • Operating cash flow of (13.44M) provides exceptional 16.64x coverage of interest expenses (808048), showing strong debt service capability.
  • Free cash flow of (13.44M) provides exceptional 16.64x coverage of interest expense (808048), showing strong debt service ability.
  • Tangible assets of 14.32M provide robust 7.02x coverage of other current liabilities 2.04M, indicating strong asset backing.
  • Cash reserves of 13.76M provide solid 18.92x coverage of other non-current liabilities 727361, indicating strong liquidity.
  • Strong cash position of 13.76M provides 6.75x coverage of other current liabilities 2.04M, indicating excellent liquidity.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 8.39M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (13.44M) shows concerning coverage of stock compensation expenses of 495145, with a -27.15 ratio indicating potential earnings quality issues.
  • Operating earnings of (13.85M) show weak coverage of depreciation charges of 21714, with a -637.69 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (13.44M) is outpaced by equity issuance of 933073 (-14.41 ratio), indicating concerning reliance on equity markets for funding operations.
  • Cash position of 13.76M provides only -17.03x coverage of interest expenses of (808048), indicating potential refinancing risks in a rising rate environment.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets -0.90 11.06
EV to Cash from Ops. EV/CFO 0.96 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT 0.93 -13.49
EV to EBITDA EV/EBITDA 0.94 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF 0.96 25.66
EV to Market Cap EV to Market Cap -3.51 203.37
EV to Revenue EV/Rev -26.42 156.31
Price to Book Value [P/B] P/B 0.34 20.59
Price to Earnings [P/E] P/E -0.28 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 17.14 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -47.67 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 6.64 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 6.45 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 6.64 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 3.47 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 24.20 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) 2.64 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -62.75 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.03 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 5.13 3.92
Current Ratio Curr Ratio (Qtr) 5.20 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Int Coverage (Qtr) 17.14 956.66
Times Interest Earned Times Interest Earned (Qtr) 17.14 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -2,831.60 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -2,836.07 -18,246.34
EBT Margin % EBT Margin % (Qtr) -2,670.56 -19,108.08
Gross Margin % Gross Margin % (Qtr) 100.00 -10.30
Net Profit Margin % Net Margin % (Qtr) -2,670.60 -19,056.96